Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2021

01-08-2021 | Melanoma | PRECLINICAL STUDIES

Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis

Authors: Bo Chen, Donghong Sun, Xiuni Qin, Xing-Hua Gao

Published in: Investigational New Drugs | Issue 4/2021

Login to get access

Summary

Melanoma is a highly aggressive malignant skin tumor with a high rate of metastasis and mortality. In this study, a comprehensive bioinformatics analysis was used to clarify the hub genes and potential drugs. Download the GSE3189, GSE22301, and GSE35388 microarray datasets from the Gene Expression Omnibus (GEO), which contains a total of 33 normal samples and 67 melanoma samples. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) approach analyze DEGs based on the DAVID. Use STRING to construct protein-protein interaction network, and use MCODE and cytoHubba plug-ins in Cytoscape to perform module analysis and identified hub genes. Use Gene Expression Profile Interactive Analysis (GEPIA) to assess the prognosis of genes in tumors. Finally, use the Drug-Gene Interaction Database (DGIdb) to screen targeted drugs related to hub genes. A total of 140 overlapping DEGs were identified from the three microarray datasets, including 59 up-regulated DEGs and 81 down-regulated DEGs. GO enrichment analysis showed that these DEGs are mainly involved in the biological process such as positive regulation of gene expression, positive regulation of cell proliferation, positive regulation of MAP kinase activity, cell migration, and negative regulation of the apoptotic process. The cellular components are concentrated in the membrane, dendritic spine, the perinuclear region of cytoplasm, extracellular exosome, and membrane raft. Molecular functions include protein homodimerization activity, calmodulin-binding, transcription factor binding, protein binding, and cytoskeletal protein binding. KEGG pathway analysis shows that these DEGs are mainly related to protein digestion and absorption, PPAR signaling pathway, signaling pathways regulating stem cells’ pluripotency, and Retinol metabolism. The 23 most closely related DEGs were identified from the PPI network and combined with the GEPIA prognostic analysis, CDH3, ESRP1, FGF2, GBP2, KCNN4, KIT, SEMA4D, and ZEB1 were selected as hub genes, which are considered to be associated with poor prognosis of melanoma closely related. Besides, ten related drugs that may have therapeutic effects on melanoma were also screened. These newly discovered genes and drugs provide new ideas for further research on melanoma.
Literature
1.
Kandolf Sekulovic L, Peris K, Stratigos A, Hauschild A, Forsea AM, Lebbe C, Lallas A, Grob JJ, Harwood C, Gogas H, Rutkowski P, Olah J, Kelleners-Smeets NWJ, Paoli J, Dummer R, Moreno-Ramirez D, Bastholt L, Putnik K, Karls R, Hoeller C, Vandersleyen V, Vieira R, Arenberger P, Bylaite-Buckinskiene M, Ocvirk J, Situm M, Weinlich G, Banjin M, Todorovic V, Ymeri A, Zhukavets A, Garbe C (2020) Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centers in 27 European countries. J Eur Acad Dermatol Venereol. https://​doi.​org/​10.​1111/​jdv.​17086
2.
3.
4.
Jeyakumar A, Chua TC, Lam AK, Gopalan V (2020) The melanoma and breast Cancer association: an overview of their 'Second primary Cancers' and the epidemiological, Genetic and Biological correlations. Crit Rev Oncol Hematol 152:102989PubMedCrossRef
5.
6.
Guo J, Qin S, Liang J, Lin T, Si L, Chen X, Chi Z, Cui C, Du N, Fan Y et al (2015) Chinese guidelines on the diagnosis and treatment of melanoma (2015 edition). Ann Transl Med 3(21):322PubMedPubMedCentral
7.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206PubMedPubMedCentralCrossRef
8.
Feero WG (2020) Bioinformatics, sequencing accuracy, and the credibility of clinical genomics. JAMA 324(19):1945–1947PubMedCrossRef
9.
Djulbegovic MB, Uversky VN (2020) Expanding the understanding of the heterogeneous nature of melanoma with bioinformatics and disorder-based proteomics. Int J Biol Macromol 150:1281–1293PubMedCrossRef
10.
Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Edgar R (2007) NCBI GEO: mining tens of millions of expression profiles--database and tools update. Nucleic Acids Res 35:D760–D765PubMedCrossRef
11.
Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, Wang Y (2005) Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11(20):7234–7242PubMedCrossRef
12.
Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, Vega YSEC, Medicherla R, Christos PJ, Shapiro R et al (2011) Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res 71(7):2561–2571PubMedPubMedCentralCrossRef
13.
Xiao D, Ohlendorf J, Chen Y, Taylor DD, Rai SN, Waigel S, Zacharias W, Hao H, McMasters KM (2012) Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One 7(10):e46874PubMedPubMedCentralCrossRef
14.
Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) Affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20(3):307–315PubMedCrossRef
15.
16.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47PubMedPubMedCentralCrossRef
17.
Chen B, Hua Z, Gong B, Tan X, Zhang S, Li Q, Chen Y, Zhang J, Li Z (2020b) Downregulation of PIF1, a potential new target of MYCN, induces apoptosis and inhibits cell migration in neuroblastoma cells. Life Sci 256:117820PubMedCrossRef
18.
Wang Y, Zhang Y, Huang Q, Li C (2018a) Integrated bioinformatics analysis reveals key candidate genes and pathways in breast cancer. Mol Med Rep 17(6):8091–8100PubMedPubMedCentral
19.
Niu J, Yan T, Guo W, Wang W, Zhao Z, Ren T, Huang Y, Zhang H, Yu Y, Liang X (2020) Identification of potential therapeutic targets and immune cell infiltration characteristics in osteosarcoma using bioinformatics strategy. Front Oncol 10:1628PubMedPubMedCentralCrossRef
20.
Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44–57
21.
Sherman BT, Huang da W, Tan Q, Guo Y, Bour S, Liu D, Stephens R, Baseler MW, Lane HC, Lempicki RA (2007) DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinforma 8:426CrossRef
22.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25(1):25–29PubMedPubMedCentralCrossRef
23.
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45(D1):D353–D361CrossRefPubMed
24.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering C (2019) STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47(D1):D607–D613PubMedCrossRef
25.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45(W1):W98–W102PubMedPubMedCentralCrossRef
26.
Freshour SL, Kiwala S, Cotto KC, Coffman AC, McMichael, JF, Song JJ, Griffith M, Griffith OL, Wagner AH (2020) Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res 49(D1):D1144–D1151
27.
Mo R, Chen C, Mi L, Ma Z, Tan Q (2020) Skin melanoma survival is not superior in females in the new stage IIID of the 8th edition of the staging system: an analysis of data from the surveillance, epidemiology, and end results (SEER) database. Ann Transl Med 8(21):1381PubMedPubMedCentralCrossRef
28.
Durbec F, Martin L, Derancourt C, Grange F (2012) Melanoma of the hand and foot: epidemiological, prognostic and genetic features. A systematic review. Br J Dermatol 166(4):727–739PubMedCrossRef
29.
30.
Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, Hernandez-Aya L, Lawrence D, Lutzky J, Miller WH Jr, Campbell KM, Delafont B, Marshall S, Mueller N, Robert C (2020) PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun 11(1):6262PubMedPubMedCentralCrossRef
31.
Wang C, Shi X, Song H, Zhang C, Wang X, Huang P, Dong A, Zhang Y, Kong D, Wang W (2020a) Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma. Biomaterials 268:120579PubMedCrossRef
32.
Jessen C, Kress JKC, Baluapuri A, Hufnagel A, Schmitz W, Kneitz S, Roth S, Marquardt A, Appenzeller S, Ade CP et al (2020) Correction: the transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression. Oncogene 39(44):6841–6855 
33.
Won YS, Kim JH, Lizardo RCM, Min HJ, Cho HD, Hong SM, Seo KI (2020) The flavonol isoquercitrin promotes mitochondrial-dependent apoptosis in SK-Mel-2 melanoma cell via the PI3K/AKT/mTOR pathway. Nutrients 12(12). https://​doi.​org/​10.​3390/​nu12123683
34.
Wang Z, Xu Q, Zhang N, Du X, Xu G, Yan X (2020b) CD146, from a melanoma cell adhesion molecule to a signaling receptor. Signal Transduct Target Ther 5(1):148PubMedPubMedCentralCrossRef
35.
Liu JF, Chen PC, Chang TM, Hou CH (2020a) Monocyte Chemoattractant Protein-1 promotes cancer cell migration via c-Raf/MAPK/AP-1 pathway and MMP-9 production in osteosarcoma. J Exp Clin Cancer Res 39(1):254PubMedPubMedCentralCrossRef
36.
Xu M, Wang J, Li H, Zhang Z, Cheng Z (2020) AIM2 inhibits colorectal cancer cell proliferation and migration through suppression of Gli1. Aging (Albany NY) 13(1):1017–1031
37.
Gomes-da-Silva LC, Jimenez AJ, Sauvat A, Xie W, Souquere S, Divoux S, Storch M, Sveinbjornsson B, Rekdal O, Arnaut LG et al (2019) Recruitment of LC3 to damaged Golgi apparatus. Cell Death Differ 26(8):1467–1484PubMedCrossRef
38.
Yang E, Wang X, Gong Z, Yu M, Wu H, Zhang D (2020) Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther 5(1):242PubMedPubMedCentralCrossRef
39.
Arnold J, Schattschneider J, Blechner C, Krisp C, Schluter H, Schweizer M, Nalaskowski M, Oliveira-Ferrer L, Windhorst S (2020) Tubulin tyrosine ligase like 4 (TTLL4) overexpression in breast cancer cells is associated with brain metastasis and alters exosome biogenesis. J Exp Clin Cancer Res 39(1):205PubMedPubMedCentralCrossRef
40.
Meerson NR, Delautier D, Durand-Schneider AM, Moreau A, Schilsky ML, Sternlieb I, Feldmann G, Maurice M (1998) Identification of B10, an alkaline phosphodiesterase of the apical plasma membrane of hepatocytes and biliary cells, in rat serum: increased levels following bile duct ligation and during the development of cholangiocarcinoma. Hepatology 27(2):563–568PubMedCrossRef
41.
Fancy RM, Kim H, Zhou T, Zinn KR, Buchsbaum DJ, Song Y (2017) Calmodulin binding to death receptor 5-mediated death-inducing signaling complex in breast Cancer cells. J Cell Biochem 118(8):2285–2294PubMedPubMedCentralCrossRef
42.
Chen Y, Pawar P, Pan G, Ma L, Liu H, McDonald JM (2008) Calmodulin binding to the Fas-mediated death-inducing signaling complex in cholangiocarcinoma cells. J Cell Biochem 103(3):788–799PubMedCrossRef
43.
Karp CM, Shukla MN, Buckley DJ, Buckley AR (2007) HRPAP20: a novel calmodulin-binding protein that increases breast cancer cell invasion. Oncogene 26(12):1780–1788PubMedCrossRef
44.
Mauro JA, Yavorski JM, Blanck G (2017) Stratifying melanoma and breast cancer TCGA datasets on the basis of the CNV of transcription factor binding sites common to proliferation- and apoptosis-effector genes. Gene 614:37–48PubMedCrossRef
45.
Liu X, Qian D, Liu H, Abbruzzese JL, Luo S, Walsh KM, Wei Q (2020b) Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer. Mol Carcinog 59(8):930–939PubMedPubMedCentralCrossRef
46.
Zhang X, Yao J, Shi H, Gao B, Zhang L (2019) LncRNA TINCR/microRNA-107/CD36 regulates cell proliferation and apoptosis in colorectal cancer via PPAR signaling pathway based on bioinformatics analysis. Biol Chem 400(5):663–675PubMedCrossRef
47.
Chen YZ, Xue JY, Chen CM, Yang BL, Xu QH, Wu F, Liu F, Ye X, Meng X, Liu GY, Shen ZZ, Shao ZM, Wu J (2012) PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy. Cancer Chemother Pharmacol 70(5):637–644PubMedCrossRef
48.
Huang R, Li Z, Li C, Wang G, Yan P, Peng L, Wang J, Zhu X, Hu P, Zhang J et al (2019) Germ cell-specific gene 1-like protein regulated by splicing factor CUGBP Elav-like family member 5 and primary bile acid biosynthesis are prognostic in glioblastoma Multiforme. Front Genet 10:1380PubMedCrossRef
49.
Jiang Y, Song H, Jiang L, Qiao Y, Yang D, Wang D, Li J (2020) Silybin prevents prostate Cancer by inhibited the ALDH1A1 expression in the retinol metabolism pathway. Front Cell Dev Biol 8:574394PubMedPubMedCentralCrossRef
50.
Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, Rhim JS, Nanus DM, Gudas LJ (2002) Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res 62(6):1654–1661PubMed
51.
Chen AC, Guo X, Derguini F, Gudas LJ (1997) Human breast cancer cells and normal mammary epithelial cells: retinol metabolism and growth inhibition by the retinol metabolite 4-oxoretinol. Cancer Res 57(20):4642–4651PubMed
52.
Hayden LJ, Satre MA (2002) Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells. Breast Cancer Res Treat 72(2):95–105PubMedCrossRef
53.
Vieira AF, Dionisio MR, Gomes M, Cameselle-Teijeiro JF, Lacerda M, Amendoeira I, Schmitt F, Paredes J (2017) P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice. Mod Pathol 30(5):698–709PubMedCrossRef
54.
Royo F, Zuniga-Garcia P, Torrano V, Loizaga A, Sanchez-Mosquera P, Ugalde-Olano A, Gonzalez E, Cortazar AR, Palomo L, Fernandez-Ruiz S et al (2016) Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer. Oncotarget 7(6):6835–6846PubMedPubMedCentralCrossRef
55.
Liu D, Wu K, Yang Y, Zhu D, Zhang C, Zhao S (2020c) Long noncoding RNA ADAMTS9-AS2 suppresses the progression of esophageal cancer by mediating CDH3 promoter methylation. Mol Carcinog 59(1):32–44PubMedCrossRef
56.
Li L, Yu S, Wu Q, Dou N, Li Y, Gao Y (2019) KLF4-mediated CDH3 Upregulation suppresses human Hepatoma cell growth and migration via GSK-3beta signaling. Int J Biol Sci 15(5):953–961PubMedPubMedCentralCrossRef
57.
Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y (2005) Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 65(8):3092–3099PubMedCrossRef
58.
Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI et al (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102(17):6092–6097PubMedPubMedCentralCrossRef
59.
Seline PC, Norris DA, Horikawa T, Fujita M, Middleton MH, Morelli JG (1996) Expression of E and P-cadherin by melanoma cells decreases in progressive melanomas and following ultraviolet radiation. J Invest Dermatol 106(6):1320–1324PubMedCrossRef
60.
61.
Zhang GM, Zheng L, He H, Song CC, Zhang ZJ, Cao XK, Lei CZ, Lan XY, Qi XL, Chen H, Huang YZ (2018) Associations of GBP2 gene copy number variations with growth traits and transcriptional expression in Chinese cattle. Gene 647:101–106PubMedCrossRef
62.
Yu S, Yu X, Sun L, Zheng Y, Chen L, Xu H, Jin J, Lan Q, Chen CC, Li M (2020) GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway. Oncogene 39(27):5042–5055PubMedCrossRef
63.
Miao Q, Ge M, Huang L (2017) Up-regulation of GBP2 is associated with neuronal apoptosis in rat brain cortex following traumatic brain injury. Neurochem Res 42(5):1515–1523PubMedCrossRef
64.
Rahvar F, Salimi M, Mozdarani H (2020) Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer. Genet Mol Biol 43(4):e20190230PubMedPubMedCentralCrossRef
65.
Guimaraes DP, Oliveira IM, de Moraes E, Paiva GR, Souza DM, Barnas C, Olmedo DB, Pinto CE, Faria PA, De Moura Gallo CV et al (2009) Interferon-inducible guanylate binding protein (GBP)-2: a novel p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer 124(2):272–279PubMedCrossRef
66.
Wang Q, Wang X, Liang Q, Wang S, Xiwen L, Pan F, Chen H, Li D (2018b) Distinct prognostic value of mRNA expression of guanylate-binding protein genes in skin cutaneous melanoma. Oncol Lett 15(5):7914–7922PubMedPubMedCentral
67.
Lai W, Chen S, Wu H, Guan Y, Liu L, Zeng Y, Zhao H, Jiang J, Chu Z (2011) PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels. Oncol Rep 26(4):909–917PubMed
68.
Jiang SH, Zhu LL, Zhang M, Li RK, Yang Q, Yan JY, Zhang C, Yang JY, Dong FY, Dai M, Hu LP, Li J, Li Q, Wang YH, Yang XM, Zhang YL, Nie HZ, Zhu L, Zhang XL, Tian GA, Zhang XX, Cao XY, Tao LY, Huang S, Jiang YS, Hua R, Qian Luo K, Gu JR, Sun YW, Hou S, Zhang ZG (2019) GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated ca(2+) signalling in a GABA-independent manner. Gut 68(11):1994–2006PubMedCrossRef
69.
Gole HK, Tharp DL, Bowles DK (2014) Upregulation of intermediate-conductance Ca2+−activated K+ channels (KCNN4) in porcine coronary smooth muscle requires NADPH oxidase 5 (NOX5). PLoS One 9(8):e105337PubMedPubMedCentralCrossRef
70.
Jiang S, Zhu L, Yang J, Hu L, Gu J, Xing X, Sun Y, Zhang Z (2017) Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer. Biochem Biophys Res Commun 494(1–2):113–119PubMedCrossRef
71.
Lai W, Liu L, Zeng Y, Wu H, Xu H, Chen S, Chu Z (2013) KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer. Med Oncol 30(2):566PubMedCrossRef
72.
Bulk E, Ay AS, Hammadi M, Ouadid-Ahidouch H, Schelhaas S, Hascher A, Rohde C, Thoennissen NH, Wiewrodt R, Schmidt E, Marra A, Hillejan L, Jacobs AH, Klein HU, Dugas M, Berdel WE, Müller-Tidow C, Schwab A (2015) Epigenetic dysregulation of KCa 3.1 channels induces poor prognosis in lung cancer. Int J Cancer 137(6):1306–1317PubMedCrossRef
73.
Lallet-Daher H, Roudbaraki M, Bavencoffe A, Mariot P, Gackiere F, Bidaux G, Urbain R, Gosset P, Delcourt P, Fleurisse L et al (2009) Intermediate-conductance Ca2+−activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene 28(15):1792–1806PubMedCrossRef
74.
Rabjerg M, Olivan-Viguera A, Hansen LK, Jensen L, Sevelsted-Moller L, Walter S, Jensen BL, Marcussen N, Kohler R (2015) High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival. PLoS One 10(4):e0122992PubMedPubMedCentralCrossRef
75.
76.
Mou P, Zeng Z, Li Q, Liu X, Xin X, Wannemacher KM, Ruan C, Li R, Brass LF, Zhu L (2013) Identification of a calmodulin-binding domain in Sema4D that regulates its exodomain shedding in platelets. Blood 121(20):4221–4230PubMedPubMedCentralCrossRef
77.
Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W, Kumanogoh A, Kikutani H, Comoglio PM, Tamagnone L, Giordano S (2008) Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 205(7):1673–1685PubMedPubMedCentralCrossRef
78.
Wang Y, Zhao H, Zhi W (2020c) SEMA4D under the posttranscriptional regulation of HuR and miR-4319 boosts cancer progression in esophageal squamous cell carcinoma. Cancer Biol Ther 21(2):122–129PubMedCrossRef
79.
Xia Y, Cai XY, Fan JQ, Zhang LL, Ren JH, Li ZY, Zhang RG, Zhu F, Wu G (2019) The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms. Int J Cancer 144(9):2227–2238PubMedCrossRef
80.
Soong J, Chen Y, Shustef EM, Scott GA (2012) Sema4D, the ligand for Plexin B1, suppresses c-met activation and migration and promotes melanocyte survival and growth. J Invest Dermatol 132(4):1230–1238PubMedCrossRef
81.
Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S, Guo W, Xing Y, Carstens RP (2010) An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 29(19):3286–3300PubMedPubMedCentralCrossRef
82.
Ishii H, Saitoh M, Sakamoto K, Kondo T, Katoh R, Tanaka S, Motizuki M, Masuyama K, Miyazawa K (2014) Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms. J Biol Chem 289(40):27386–27399PubMedPubMedCentralCrossRef
83.
Vadlamudi Y, Dey DK, Kang SC (2020) Emerging multi-cancer regulatory role of ESRP1: orchestration of alternative splicing to control EMT. Curr Cancer Drug Targets 20(9):654–665PubMedCrossRef
84.
Yao J, Caballero OL, Huang Y, Lin C, Rimoldi D, Behren A, Cebon JS, Hung MC, Weinstein JN, Strausberg RL, Zhao Q (2016) Altered expression and splicing of ESRP1 in malignant melanoma correlates with epithelial-mesenchymal status and tumor-associated immune Cytolytic activity. Cancer Immunol Res 4(6):552–561PubMedCrossRef
85.
Ueda J, Matsuda Y, Yamahatsu K, Uchida E, Naito Z, Korc M, Ishiwata T (2014) Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases. Oncogene 33(36):4485–4495PubMedCrossRef
86.
Deng G, Zhou X, Chen L, Yao Y, Li J, Zhang Y, Luo C, Sun L, Tang J (2020a) High expression of ESRP1 regulated by circ-0005585 promotes cell colonization in ovarian cancer. Cancer Cell Int 20:174PubMedPubMedCentralCrossRef
87.
88.
Im JH, Buzzelli JN, Jones K, Franchini F, Gordon-Weeks A, Markelc B, Chen J, Kim J, Cao Y, Muschel RJ (2020) FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy. Nat Commun 11(1):4064PubMedPubMedCentralCrossRef
89.
Wehrle-Haller B (2003) The role of kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res 16(3):287–296PubMedCrossRef
90.
Tetu P, Delyon J, Andre J, Reger de Moura C, Sabbah M, Ghanem GE, Battistella M, Mourah S, Lebbe C, Dumaz N (2020) FGF2 induces resistance to nilotinib through MAPK pathway activation in KIT mutated melanoma. Cancers (Basel) 12(5). https://​doi.​org/​10.​3390/​cancers12051062
91.
Lefevre G, Babchia N, Calipel A, Mouriaux F, Faussat AM, Mrzyk S, Mascarelli F (2009) Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest Ophthalmol Vis Sci 50(3):1047–1057PubMedCrossRef
92.
Yu Y, Gao S, Li Q, Wang C, Lai X, Chen X, Wang R, Di J, Li T, Wang W et al (2012) The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo. J Cancer Res Clin Oncol 138(8):1321–1328PubMedCrossRef
93.
Baljinnyam E, Umemura M, Chuang C, De Lorenzo MS, Iwatsubo M, Chen S, Goydos JS, Ishikawa Y, Whitelock JM, Iwatsubo K (2014) Epac1 increases migration of endothelial cells and melanoma cells via FGF2-mediated paracrine signaling. Pigment Cell Melanoma Res 27(4):611–620PubMedPubMedCentralCrossRef
94.
Higashi Y, Moribe H, Takagi T, Sekido R, Kawakami K, Kikutani H, Kondoh H (1997) Impairment of T cell development in deltaEF1 mutant mice. J Exp Med 185(8):1467–1479PubMedPubMedCentralCrossRef
95.
Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128(4):1267–1282PubMedPubMedCentralCrossRef
96.
Liang L, Zhang Z, Qin X, Gao Y, Zhao P, Liu J, Zeng W (2018) Gambogic acid inhibits melanoma through regulation of miR-199a-3p/ZEB1 Signalling. Basic Clin Pharmacol Toxicol 123(6):692–703PubMedCrossRef
97.
Zhu L, Liu Z, Dong R, Wang X, Zhang M, Guo X, Yu N, Zeng A (2019) MicroRNA-3662 targets ZEB1 and attenuates the invasion of the highly aggressive melanoma cell line A375. Cancer Manag Res 11:5845–5856PubMedPubMedCentralCrossRef
98.
Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, Jin M, O'Sullivan C, Cummins E, Lambert M et al (2016) Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART molecule with extended half-life for the treatment of cancer. Antibodies (Basel) 5(1). https://​doi.​org/​10.​3390/​antib5010006
99.
Naujokat C, Fuchs D, Opelz G (2010) Salinomycin in cancer: a new mission for an old agent. Mol Med Rep 3(4):555–559PubMedCrossRef
100.
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4):645–659PubMedPubMedCentralCrossRef
101.
Liu Y, Hao Y, Li Y, Zheng Y, Dai J, Zhong F, Wei W, Fang Z (2020d) Salinomycin induces autophagic cell death in salinomycin-sensitive melanoma cells through inhibition of autophagic flux. Sci Rep 10(1):18515PubMedPubMedCentralCrossRef
102.
Zhou J, Liu S, Wang Y, Dai W, Zou H, Wang S, Zhang J, Pan J (2019) Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma. Mol Cancer 18(1):159PubMedPubMedCentralCrossRef
103.
Ataga KI, Stocker J (2009) Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin Investig Drugs 18(2):231–239PubMedCrossRef
104.
Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P (2017) Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World J Gastroenterol 23(23):4181–4190PubMedPubMedCentralCrossRef
105.
Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE (2019) Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. Br J Clin Pharmacol 85(10):2310–2320PubMedPubMedCentralCrossRef
106.
Quesnot N, Bucher S, Gade C, Vlach M, Vene E, Valenca S, Gicquel T, Holst H, Robin MA, Loyer P (2018) Production of chlorzoxazone glucuronides via cytochrome P4502E1 dependent and independent pathways in human hepatocytes. Arch Toxicol 92(10):3077–3091PubMedCrossRef
107.
Lu T, Liang WZ, Hao LJ, Kuo CC, Shieh P, Chou CT, Jan CR (2019) Action of chlorzoxazone on ca(2)(+)movement and viability in human oral cancer cells. Chin J Phys 62(3):123–130CrossRef
108.
Deng L, Li H, Su X, Zhang Y, Xu H, Fan L, Fan J, Han Q, Bai X, Zhao RC (2020b) Chlorzoxazone, a small molecule drug, augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation. Cell Death Dis 11(3):158PubMedPubMedCentralCrossRef
109.
Eamlamnam K, Patumraj S, Visedopas N, Thong-Ngam D (2006) Effects of Aloe vera and sucralfate on gastric microcirculatory changes, cytokine levels and gastric ulcer healing in rats. World J Gastroenterol 12(13):2034–2039PubMedPubMedCentralCrossRef
110.
Zur E (2019) Oral viscous Sucralfate gel for post-procedural treatment of Barrett's esophagus. Int J Pharm Compd 23(5):376–381PubMed
111.
Falkowski S, Trouillas P, Duroux JL, Bonnetblanc JM, Clavere P (2011) Radiodermatitis prevention with sucralfate in breast cancer: fundamental and clinical studies. Support Care Cancer 19(1):57–65PubMedCrossRef
112.
Kneebone A, Mameghan H, Bolin T, Berry M, Turner S, Kearsley J, Graham P, Fisher R, Delaney G (2004) Effect of oral sucralfate on late rectal injury associated with radiotherapy for prostate cancer: a double-blind, randomized trial. Int J Radiat Oncol Biol Phys 60(4):1088–1097PubMedCrossRef
113.
Etiz D, Erkal HS, Serin M, Kucuk B, Hepari A, Elhan AH, Tulunay O, Cakmak A (2000) Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncol 36(1):116–120PubMedCrossRef
114.
115.
Cocorocchio E, Pala L, Conforti F, Guerini-Rocco E, De Pas T, Ferrucci PF (2020) Successful treatment with avapritinib in patient with mucosal metastatic melanoma. Ther Adv Med Oncol 12:1758835920946158PubMedPubMedCentralCrossRef
116.
Lubke J, Naumann N, Kluger S, Schwaab J, Metzgeroth G, Evans E, Gardino AK, Lengauer C, Hofmann WK, Fabarius A et al (2019) Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Leukemia 33(5):1195–1205PubMedPubMedCentralCrossRef
117.
118.
Tajima K, Hattori T, Takahashi H, Katahira H, Narimatsu A, Kumakura S, Goto H (2018) Rebamipide suppresses TNF-alpha production and macrophage infiltration in the conjunctiva. Vet Ophthalmol 21(4):347–352PubMedCrossRef
119.
Ueno T, Zenda S, Konishi T, Yurikusa T, Shibasaki Y, Nagamoto H, Fujii M (2019) The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer. Int J Clin Oncol 24(3):241–247PubMedCrossRef
120.
Fukui K, Yachi K, Yoshida H, Tanji K, Matsumiya T, Hayakari R, Tsuruga K, Tanaka H, Imaizumi T (2017) Rebamipide reduces amyloid-beta 1-42 (Abeta42) production and ameliorates Abeta43-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells. Neurosci Res 124:40–50PubMedCrossRef
121.
Tanigawa T, Pai R, Arakawa T, Tarnawski AS (2007) Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci 52(1):240–247PubMedCrossRef
122.
Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD (2019) Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol 187(4):488–501PubMedPubMedCentralCrossRef
123.
Papadopoulos KP, Ben-Ami E, Patnaik A, Trone D, Li J, Demetri GD (2018) Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. BMC Cancer 18(1):790PubMedPubMedCentralCrossRef
124.
Herbert KE, Prince HM, Ritchie DS, Seymour JF (2010) The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Expert Opin Biol Ther 10(1):113–125PubMedCrossRef
125.
Motawi TM, Sadik NA, Fahim SA, Shouman SA (2015) Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact 233:147–156PubMedCrossRef
126.
Adinolfi B, Carpi S, Romanini A, Da Pozzo E, Castagna M, Costa B, Martini C, Olesen SP, Schmitt N, Breschi MC et al (2015) Analysis of the antitumor activity of Clotrimazole on A375 human melanoma cells. Anticancer Res 35(7):3781–3786PubMed
127.
Penso J, Beitner R (1998) Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol 342(1):113–117PubMedCrossRef
Metadata
Title
Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis
Authors
Bo Chen
Donghong Sun
Xiuni Qin
Xing-Hua Gao
Publication date
01-08-2021
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2021
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-021-01072-y

Other articles of this Issue 4/2021

Investigational New Drugs 4/2021 Go to the issue

PHASE I STUDIES

Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance)

PHASE I STUDIES

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

SHORT REPORT

AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis

CLINICAL TRIAL METHODOLOGY

Identify potential miRNA-mRNA regulatory networks contributing to high-risk neuroblastoma

Review

System Xc−: a key regulatory target of ferroptosis in cancer

REVIEW

Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits